Home > Oncology > ASCO 2020 > Genitourinary Cancer > First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel

First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel

Expert
Prof. Michael S. Hofman, Peter MacCallum Cancer Centre, Australia
Conference
ASCO 2020
Trial
TheraP
TheraP is the first (non-blinded) trial comparing Lu-PSMA to an active therapy with cabazitaxel in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel. Results demonstrated that Lu-PSMA has high activity and relatively low toxicity, consistent with the results of prior single-centre phase 2 data. Lu-PSMA appears to represent a favourable treatment option compared with cabazitaxel in a selected population with high PSMA expression. In the last 2 decades, several life prolonging therapies have been approved for the treatment of mCRPC, including docetaxel, cabazitaxel, abiraterone, enzalutamide, sipuleucel-T, and 223Ra. Recently, 177Lutetium-PSMA-617 (Lu-PSMA) has been developed. Lu-PSMA is a radiolabelled small molecule which binds with high affinity to prostate-specific membrane antigen (PSMA), a cell surface glycoprotein overexpressed in metastatic prostate cancer. This enables delivery of hig...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on